{"organizations": [], "uuid": "c0afbf692c30f3be1a3df80a68714a84d0e57f2e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530625?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Series B round totals $75mm for Ovid Therapeutics", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Series B round totals $75mm for Ovid Therapeutics", "spam_score": 0.0, "site_type": "news", "published": "2015-08-15T02:40:00.000+03:00", "replies_count": 0, "uuid": "c0afbf692c30f3be1a3df80a68714a84d0e57f2e"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530625?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Series B round totals $75mm for Ovid Therapeutics", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Series B round totals $75mm for Ovid Therapeutics Deal Date: Aug-01-2015 / Deal # 201530625 Executive Summary \nFidelity Management and Research Co. led a $75mm Series B financing for Ovid Therapeutics Inc. (orphan brain diseases). Other new backers included Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, Cormorant Asset Management, and undisclosed blue chip mutual funds and life science investors. Returning shareholders including DoubleLine Equity Healthcare Fund also joined. Cowen & Co. was the placement agent.", "external_links": [], "published": "2015-08-15T02:40:00.000+03:00", "crawled": "2015-08-15T14:51:26.290+03:00", "highlightTitle": ""}